News
Clinical Trials Arena on MSN17h
SynOx completes enrolment in Phase III trial of emactuzumab for TGCTSynOx Therapeutics has completed subject enrolment in its multi-centre Phase III TANGENT trial of the humanised IgG1 ...
Pancreatic cancer cells are known for being hard to treat, partly because they change the environment around them to block ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback